Novel protein targeted therapy of metastatic melanoma

Current Pharmaceutical Design

Volumn 9, Issue 25, 2003, Pages 2060-2066

  Frankel, Arthur E ^a   Koo, Han Mo ^b   Leppla, Stephen H ^c   Duesbery, Nicholas S ^b   Vande Woude, George F ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTHRAX TOXIN; ANTINEOPLASTIC AGENT; BACTERIAL ANTIGEN; DACARBAZINE; GANGLIOSIDE GM2; INTERFERON; INTERLEUKIN 2; MELANOMA VACCINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN; RAS PROTEIN; TEMOZOLOMIDE;

ANOREXIA; BACILLUS ANTHRACIS; BINDING KINETICS; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVITY; CELL PROLIFERATION; CELL SHAPE; CHILL; DEPRESSION; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROPORATION; ENZYME INACTIVATION; EXCISION; FEVER; GENE MUTATION; HUMAN; INHIBITION KINETICS; LETHAL GENE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS POTENTIAL; MOLECULAR MECHANICS; MYALGIA; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TARGETING; RELAPSE; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; THREE DIMENSIONAL IMAGING; TISSUE CULTURE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; DRUG DESIGN; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 0141761371     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454162     Document Type: Review

References (64)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J Clin 2001; 51: 15-36.
2. MacKie RM. Incidence, risk factors and prevention of melanoma. Eur J Cancer 1998; 34 Suppl 3: S3-S6.
3. Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol 2001; 137: 1493-1496.
4. Tsao H. Update on familial cancer syndromes and the skin. J Am Acad Dermatol 2000; 42: 939-969.
5. Balch CM, Buzaid A, Atkins MB. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88: 1484-1491.
6. Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Research 2000; 10: 81-100.
7. Curry BJ, Farrelly M, Hersey P. Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma. Melanoma Research 1999; 9: 557-571.
8. Veronesi U, Cascinelli N, Adamus J. Thin stage I primary cutaneous melanoma. Comparison of excision with margins of 1 cm or 3 cm. New England J Med 1988; 318: 1159-1162.
9. Balch CM, Smith TJ, Jewell WR, Barnihill R. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262-269.
10. Heaton KM, Sussman JJ, Gershenwald JE. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 1998; 4: 322-328.
11. Slingluff CF, Stidham KR, Ricci WM, Stanley WE, Seigler HF. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg 1994; 219: 120-130.
12. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981; 193: 377-383.
13. Eggermont AMM. European approach to the treatment of malignant melanoma. Curr Opin Oncol 2002; 14: 205-211.
14. Gershenwald JE, Colome MI, Lee JE. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16: 2253-2264.
15. van der Velde-Zimmerman D, Schipper ME, De Weger RA, Hennipman A, Borel B, Rinkes IH. Sentinel node biopsies in melanoma patients: a protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR. Ann Surg Oncol 2000; 7: 51-58.
16. Ariyan S, Poo, WJ. Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. Surgery 1998; 123: 335-340.
17. Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996; 83: 509-514.
18. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Intl J Radiat Oncol Biol Phys 1999; 44: 607-621.
19. Lens MB, Dawes M. Interferon alpha therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20: 1818-1825.
20. Eggermont AMM. Role of interferon-alpha in malignant melanoma remains to be determined. Eur J Cancer 2001; 37: 2147-2153.
21. Sosman JA, Unger JM, Liu PY. Significant impact of HLA class I alleles on outcome in T3N0M0 melanoma patients treated with Melacine (MEL): an allogeneic cell lysate vaccine: prospective analysis of Southwest Oncology Group (SWOG)-9035. Proc ASCO 2001; 20: 351.
22. Morton DL. Adjuvant immunotherapy of malignant melanoma: status of clinical trials at UCLA. Int J Immunother 1986; 2: 31-36.
23. Livingstone PO, Wong GYC, Adluri S. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036-1044.
24. Ryan L, Kramer A, Borden EC. Prognostic factors in metastatic melanoma. Cancer 1993; 71: 2995-3005.
25. Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, et al. Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma Research 2002; 12: 381-387.
26. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine 1998; 4: 328-332.
27. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002; 20: 2058-2066.
28. Kirkwood JM, Ibrahim JG, Sosman JA. High-dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-2380.
29. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002; 20: 2067-2075.
30. Khong HT, Rosenberg SA. The Waardenburg Syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Research 2002; 62: 3020-3023.
31. Khong HT, Rosenberg SA. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J Immunol 2002; 168: 951-956.
32. Setlow RB. Shedding light on proteins, nucleic acids, cells, human and fish. Mutation Research 2002; 511: 1-14.
33. Davis H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
34. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001; 20: 8125-8135.
35. Valverde P, Healy E, Sikkink S. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996; 5: 1663-1666.
36. Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Research 1988; 3: 177-186.
37. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-211.
38. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Vande Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci USA 2002; 99: 3052-3057.
39. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD. et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998; 280: 734-737.
40. Duesbery NS, V?inde Woude, GF. Anthrax toxins. Cell Mol Life Sci 1999; 55: 1599-1609.
41. Petosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC. Crystal structure of the anthrax toxin protective antigen. Nature 1997; 385: 833-838.
42. Pannifer AD, Wong TY, Schwarzenbacher R, Renatus M, Petosa C, Bienkowska J. et al. Crystal structure of the anthrax lethal factor. Nature 2001; 414: 229-233.
43. Varughese M, Teixerira AV, Liu S, Leppla SH. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immun 1999; 67: 1860-1865.
44. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JAT. Identification of the cellular receptor for anthrax toxin. Nature 2001; 414: 225-229.
45. Mogridge J, Mourez M, Collier RJ. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J Bacteriol 2001; 183: 2111-2116.
46. Cunningham K, Lacy DB, Mogridge J, Collier RJ. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc Natl Acad Sci USA 2002; 99: 7049-7053.
47. Mogridge J, Cunningham K, Lacy DB, Mourez M, Collier RJ. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc Natl Acad Sci USA 2002; 99: 7045-7048.
48. Mogridge J, Cunningham K, Collier RJ. Stochiometry of anthrax toxin complexes. Biochemistry 2002; 41: 1079-1082.
49. Arora N, Leppla SH. Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells. Infect Immun 1994; 62: 4955-4961.
50. Beauregard KE, Collier RJ, Swanson JA. Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization. Cell Microbiol 2000; 2: 251-258.
51. Sellman BR, Mourez M, Collier RJ. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 2001; 292: 695-697.
52. Batra S, Gupta P, Chauhan V, Singh A, Bhatnagar R. Trp 346 and Leu 352 residues in protective antigen are required for the expression of anthrax lethal toxin activity. Biochem Biophys Res Commun 2001; 281: 186-192.
53. Miller CJ, Elliott JL, Collier RJ. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 1999; 38: 10432-10441.
54. Klimpel KR, Arora N, Leppla SH. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol 1994; 13: 1093-1100.
55. Leppla SH. Production and purification of anthrax toxin. Methods Enzymol 1988; 165: 103-116.
56. Park S, Leppla SH. Optimized production and purification of Bacillus anthracis lethal factor. Protein Expression and Purification 2000; 18: 293-302.
57. Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, Leppla SH. et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci USA 2001; 98: 4089-4094.
58. Ezzell JW, Ivins BE, Leppla SH. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect Immun 1984; 45: 761-767.
59. Welkos SL, Keener TJ, Gibbs PH. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun 1986; 51: 795-800.
60. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Research 2000; 60: 6061-6067.
61. Giambernardi TA, Sakaguchi AY, Gluhak J, Pavlin D, Troyer DA, Das G. et al. Neutrophil collagenase (MMP-8) is expressed during early development in neural crest cells as well as in adult melanoma cells. Matrix Biol 2001; 20: 577-587.
62. Nottage M, Siu LL. Rationale for Ras and raf-kinase as a target for cancer therapeutics. Curr Pharm Des 2002; 8(25): 2231-42.
63. Pervaiz S. Anti-cancer drugs of today and tomorrow: are we close to making the turn from treating to curing cancer? Curr Pharm Des 2002; 8(19): 1723-34.
64. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002; 8(25): 2255-7.